查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1917882

近視與老花眼治療市場－2026-2031年預測

Myopia and Presbyopia Treatment Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

近視和老花眼治療市場預計將從 2025 年的 284.34 億美元成長到 2031 年的 463.07 億美元，複合年成長率為 8.47%。

近視和老花眼治療市場涵蓋了針對全球兩種最常見屈光不正的一系列動態且不斷擴展的矯正和治療方案。近視主要由眼軸長度延長引起，而老花眼則由水晶體調節功能老齡化增加而下降所引起。推動這兩個市場共同發展的，是強大的、相互關聯的人口結構和生活方式趨勢。人口老化、現代生活方式的改變以及持續的技術創新，導致全球近視和老花眼患病率不斷上升，從而在外科手術、藥物治療和視力矯正等領域創造了持續的需求。

近視治療領域的一個重要且強大的促進因素是全球近視盛行率的不斷上升，尤其是在年輕人中，近視的發病年齡越來越早，病情進展也越來越快。這一趨勢與都市化相關的生活方式因素密切相關，例如長時間近距離用眼（過度使用電子設備）、戶外活動減少以及學業壓力。這些環境和行為模式的改變導致越來越多的年輕患者需要接受治療，這些治療不僅能矯正屈光，還能延緩近視進展，進而降低長期眼部健康風險。

同時，全球人口老化正直接且不可逆轉地推動老花眼治療領域的發展。老花眼，老齡化，隨著40歲以上人口比例的增加，代表著一個巨大且不斷成長的潛在市場。這群人通常更注重健康，擁有更大的自由裁量權收入，因此他們尋求的解決方案不僅限於普通的閱讀眼鏡，還包括先進的光學矯正、手術治療以及能夠恢復功能性近視力並支持積極生活方式的新興藥物療法。

技術進步是推動整個市場發展的關鍵促進者。在外科矯正領域，創新技術不斷提升治療效果。在近視矯正方面，波前導引和角膜地形圖導引的雷射手術（LASIK、PRK、SMILE）提高了手術的精確度和個人化程度。在老花眼矯正方面，進展包括景深擴展型和多焦點人工水晶體（IOL）、角膜嵌體以及基於雷射的老花眼矯正技術。除了手術之外，老花眼的藥物治療領域也正在進行大量的研發工作，新型眼藥水正在研究透過調節瞳孔大小和景深來暫時改善近距離力，這預示著老花眼治療模式轉移。

除了技術進步之外，公眾和專業人士的意識提升也發揮關鍵作用。醫療機構、專業協會和產業相關人員的教育努力，正推動人們日益認知到，眼部疾病和眼瞼疾病都是可治療的健康問題，而非無法避免的不便。這種意識的提高促進了早期診斷，鼓勵患者與眼科醫生討論各種治療方案，並增加了患者對針對特定生活方式的個人化治療方法的需求，所有這些都在推動市場成長和發展。

從區域來看，北美仍然是領先且成熟的市場。屈光不正的高發生率、完善的先進眼科中心體系、較高的患者意識以及許多手術項目有利的報銷機制，都鞏固了北美市場的地位。此外，該地區還聚集了許多大型醫療設備和製藥公司，促進了創新技術的快速引進週期，並使其成為臨床研究和開發的重要中心。

儘管成長要素強勁，但市場仍面臨許多限制因素，影響眼科醫療服務的可近性和普及率。其中一個主要障礙是許多先進治療方案，特別是選擇性屈光矯正手術和高階人工水晶體（IOL）的高昂自付費用，這些費用可能無法完全由保險覆蓋。這種對價格的敏感度會限制治療的普及，尤其是在價格敏感人群中。此外，患者對手術和新型藥物的安全性、有效性和潛在副作用的擔憂也會造成猶豫，因此需要醫療專業人員進行充分的諮詢和建立信任。獲得專業眼科護理服務和先進診斷技術的途徑仍然不均衡，尤其是在農村和醫療服務不足的地區，造成了治療缺口。

眼科器材產業的競爭格局由大規模眼科器材公司、專業製藥公司和光學產品製造商組成。領先企業憑藉在雷射平台和人工水晶體設計方面的技術優勢、可靠的臨床數據支持其安全性和有效性，以及為眼科專業人員提供的全面服務和培訓支援展開競爭。其策略重點領域包括：開發延緩近視進展的聯合療法；研發可減少閃光感的下一代人工水晶體矯正型人工水晶體；以及將首個獲得FDA核准的老花眼藥物推向市場。

總之，近視和老花眼治療市場正從簡單的屈光矯正更全面的模式發展，涵蓋緩解疾病、功能恢復和個人化管理。人口結構和生活方式的必然變化推動了全球患者群體的擴大，從而為其成長提供了結構性支撐。未來市場發展將取決於新型藥物的成功商業化、手術效果和患者體驗的持續改善，以及提高先進療法的成本效益和可及性的努力。這些因素共同作用，使市場能夠持續創新和擴張，以滿足日益成長且老化的全球人口的視覺需求。

本報告的主要優勢：

  • 深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
  • 競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
  • 市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
  • 可操作的建議：利用這些見解，在動態環境中做出策略決策，並開拓新的商機和收入來源。
  • 受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

您打算如何使用這份報告？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

  • 2021年至2025年的歷史數據和2026年至2031年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 按業務板塊和地區（包括國家）分類的收入和預測評估
  • 公司概況（策略、產品、財務資訊、關鍵發展等）

目錄

第1章執行摘要

第2章 市場概覽

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策與法規
  • 策略建議

第4章 技術展望

第5章 依疾病類型分類的近視與老花眼治療市場

  • 介紹
  • 近視
  • 老花眼

第6章 近視和老花眼治療市場（依治療方法分類）

  • 介紹
  • 處方鏡片
  • 隱形眼鏡
  • 外科手術
  • 藥物治療

第7章 按最終使用者分類的近視和老花眼治療市場

  • 介紹
  • 醫院
  • 眼科診所
  • 其他

第8章：各地區近視與老花眼治療市場

  • 介紹
  • 北美洲
    • 依疾病類型
    • 透過治療方法
    • 最終用戶
    • 按國家/地區
      • 美國
      • 加拿大
      • 墨西哥
  • 南美洲
    • 依疾病類型
    • 透過治療方法
    • 最終用戶
    • 按國家/地區
      • 巴西
      • 阿根廷
      • 其他
  • 歐洲
    • 依疾病類型
    • 透過治療方法
    • 最終用戶
    • 按國家/地區
      • 德國
      • 法國
      • 英國
      • 西班牙
      • 義大利
      • 其他
  • 中東和非洲
    • 依疾病類型
    • 透過治療方法
    • 最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 其他
  • 亞太地區
    • 依疾病類型
    • 透過治療方法
    • 最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 印尼
      • 泰國
      • 台灣
      • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Ziemer Ophthalmic Systems AG
  • ALCON Inc.
  • Bausch Health Companies Inc.
  • Essilor Ltd
  • Johnson & Johnson
  • NIDEK CO. LTD
  • Topcon Corporation
  • Carl Zeiss
  • AbbVie
  • Cooper Companies Inc

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061615898

Myopia And Presbyopia Treatment Market is forecasted to rise at a 8.47% CAGR, reaching USD 46.307 billion in 2031 from USD 28.434 billion in 2025.

The myopia and presbyopia treatment market encompasses a dynamic and expanding spectrum of corrective and therapeutic solutions for two of the most prevalent refractive errors globally. While distinct in their etiology-myopia primarily driven by axial elongation and presbyopia by age-related loss of lens accommodation-their combined market is propelled by powerful, interconnected demographic and lifestyle trends. The growing global prevalence of both conditions, fueled by an aging population and modern behavioral shifts, alongside continuous technological innovation, is creating sustained demand across surgical, pharmacological, and optical correction segments.

A fundamental and potent driver for the myopia treatment segment is the rising global prevalence of myopia, particularly its early onset and progression in younger populations. This trend is strongly correlated with lifestyle factors associated with urbanization, including increased engagement in prolonged near-work activities (extensive digital device usage), reduced time spent outdoors, and educational pressures. The shift towards these environmental and behavioral patterns is creating a larger and younger patient pool requiring intervention, not only for refractive correction but increasingly for treatments aimed at slowing myopic progression itself to mitigate long-term ocular health risks.

Concurrently, the presbyopia treatment segment is being directly and irreversibly driven by global demographic aging. As a natural, age-related condition affecting near vision, the increasing proportion of the population over the age of 40 represents a vast and expanding addressable market. This demographic is typically more health-aware and possesses greater discretionary spending power, seeking solutions that extend beyond basic reading glasses to more advanced optical corrections, surgical options, and emerging pharmacological therapies that restore functional near vision and support an active lifestyle.

Technological advancement serves as a critical catalyst across the entire market. In surgical correction, innovations continue to refine outcomes. For myopia, wavefront-guided and topography-guided laser procedures (LASIK, PRK, SMILE) enhance precision and customization. For presbyopia, advancements include extended depth-of-focus and multifocal intraocular lenses (IOLs), corneal inlays, and laser-based presbyopia correction techniques. Beyond surgery, significant research and development is focused on pharmacological treatments for presbyopia, investigating novel topical agents designed to temporarily improve near vision by modulating pupil size or depth of focus, representing a potential paradigm shift towards non-invasive management.

Parallel to technological progress is the role of increasing public and professional awareness. Educational campaigns by healthcare organizations, professional societies, and industry participants are elevating the understanding of both conditions as treatable health issues rather than inevitable inconveniences. This heightened awareness is encouraging earlier diagnosis, discussion of a broader range of treatment options with eye care professionals, and greater patient demand for interventions that align with specific lifestyle needs, thereby driving market growth and sophistication.

Geographically, North America remains a dominant and mature market. This position is reinforced by a high prevalence of refractive errors, a well-established infrastructure of advanced ophthalmic care centers, high patient awareness, and favorable reimbursement frameworks for many surgical procedures. The region's concentration of leading medical device and pharmaceutical companies also fosters a rapid adoption cycle for innovative technologies and serves as a primary hub for clinical research and development.

Despite strong growth drivers, the market faces several restraints that impact accessibility and adoption. A significant barrier is the high out-of-pocket cost associated with many advanced treatments, particularly elective refractive surgeries and premium IOLs, which may not be fully covered by insurance plans. This cost sensitivity can limit uptake, especially in price-conscious segments. Furthermore, concerns regarding the safety, efficacy, and potential side effects of surgical procedures or novel pharmacological agents can create patient hesitancy, necessitating extensive counseling and trust-building by practitioners. Access to specialized eye care services and advanced diagnostic technology also remains uneven, particularly in rural and underserved regions globally, creating disparities in treatment availability.

The competitive landscape is characterized by a mix of large, diversified ophthalmic device companies, specialized pharmaceutical firms, and optical product manufacturers. Key players compete on the basis of technological leadership in laser platforms and IOL design, robust clinical data supporting safety and efficacy, and comprehensive service and training support for eye care professionals. Strategic focus areas include developing combination therapies for myopia control, next-generation presbyopia-correcting IOLs with reduced dysphotopsias, and bringing the first wave of FDA-approved pharmacological presbyopia treatments to market.

In conclusion, the myopia and presbyopia treatment market is evolving from a focus solely on refractive correction towards a more holistic model encompassing disease modification, functional restoration, and personalized management. Its growth is structurally supported by inescapable demographic and lifestyle trends that are expanding the global patient base. Future market development will be shaped by the successful commercialization of novel pharmacological agents, continued refinement of surgical outcomes and patient experience, and efforts to improve the cost-effectiveness and accessibility of advanced treatments. The convergence of these factors positions the market for ongoing innovation and expansion as it addresses the visual needs of a growing and aging global population.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Myopia and Presbyopia Treatment Market Segmentation

  • By Disease Type
  • Myopia
  • Presbyopia
  • By Treatment Type
  • Prescription Lenses
  • Contact Lenses
  • Surgery
  • Medication
  • By End-User
  • Hospitals
  • Eyecare Centers & Clinics
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY DISEASE TYPE

  • 5.1. Introduction
  • 5.2. Myopia
  • 5.3. Presbyopia

6. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY TREATMENT TYPE

  • 6.1. Introduction
  • 6.2. Prescription Lenses
  • 6.3. Contact Lenses
  • 6.4. Surgery
  • 6.5. Medication

7. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Eyecare Centers & Clinics
  • 7.4. Others

8. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Disease Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Disease Type
    • 8.3.2. By Treatment Type
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Disease Type
    • 8.4.2. By Treatment Type
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. France
      • 8.4.4.3. United Kingdom
      • 8.4.4.4. Spain
      • 8.4.4.5. Italy
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Disease Type
    • 8.5.2. By Treatment Type
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Disease Type
    • 8.6.2. By Treatment Type
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. India
      • 8.6.4.3. Japan
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Thailand
      • 8.6.4.7. Taiwan
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Ziemer Ophthalmic Systems AG
  • 10.2. ALCON Inc.
  • 10.3. Bausch Health Companies Inc.
  • 10.4. Essilor Ltd
  • 10.5. Johnson & Johnson
  • 10.6. NIDEK CO. LTD
  • 10.7. Topcon Corporation
  • 10.8. Carl Zeiss
  • 10.9. AbbVie
  • 10.10. Cooper Companies Inc

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations